Laboratory Emitter Plans Large Private Placement

Jakarta — PT Diagnos Laboratorium Utama Tbk (DGNS), a listed laboratory diagnostics company, plans to conduct a capital increase without pre-emptive rights (known as PMTHMETD in Indonesian regulatory terminology) or private placement.

The company will issue a maximum of 125 million new shares, equivalent to no more than 10 per cent of all issued and paid-up shares of the company. The shares to be issued are registered shares with a nominal value of Rp25 per share, consistent with the nominal value of currently outstanding shares.

“The implementation of the PMTHMETD will be conducted in compliance with applicable capital market regulations, including provisions concerning the execution price in accordance with regulations,” according to the latest prospectus published on Friday, 27 February 2026.

DGNS management explained that the private placement represents a strategic initiative to strengthen the company’s capital structure in line with growth in business operations. The private placement plan will be presented at an Extraordinary General Meeting of Shareholders (RUPSLB) scheduled for 6 April 2026.

For context, DGNS is an operating subsidiary of PT Bundamedik Tbk (BMHS), focusing on pathology and genomic laboratory services. The company provides integrated and comprehensive diagnostic services supporting patients throughout their life stages, from pregnancy planning and prenatal care, through child development, productive years, to geriatric care services.